Skip to main content
XRAY
NASDAQ Industrial Applications And Services

Dentsply Sirona Reports Q1 Net Loss, Significant Margin Decline Amid Restructuring & Major Legal Challenges

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$11.55
Mkt Cap
$2.278B
52W Low
$9.85
52W High
$17.18
Market data snapshot near publication time

summarizeSummary

Dentsply Sirona reported a net loss of $10 million and a significant drop in gross profit margin for Q1 2026, alongside ongoing restructuring efforts and substantial legal and tax contingencies.


check_boxKey Events

  • Q1 Financial Performance Deteriorates

    The company swung to a net loss of $10 million in Q1 2026 from a $20 million net income in Q1 2025. Gross profit margin fell significantly from 53.0% to 48.5%, and net sales, while flat year-over-year, declined 6.7% on a constant currency basis. This follows the Q1 earnings announcement via an 8-K and news on the same day.

  • Major Restructuring Underway

    Dentsply Sirona incurred $60 million in non-recurring charges in Q1 2026 for a new restructuring plan (2026 Plan), which is expected to generate $120 million in annualized cost savings. Total charges for the plan are projected to be $60-$65 million.

  • Dividend Eliminated

    The Board of Directors eliminated quarterly dividends on common stock starting in Q1 2026, a decision previously announced in February 2026 as part of a broader restructuring effort.

  • Significant Legal and Tax Contingencies

    The company faces multiple ongoing securities and derivative litigations. Notably, the IRS has proposed a $451 million adjustment related to a 2016 stock redemption, which the company is contesting. A German prosecutor's office is also investigating intercompany loans from 2016-2017.


auto_awesomeAnalysis

The Q1 2026 results show a significant deterioration in Dentsply Sirona's financial health, marked by a swing to a net loss and substantial margin compression. While the ongoing restructuring plan aims to improve operational efficiency and generate significant cost savings, the immediate impact is negative. The elimination of the dividend, though previously announced, reinforces the company's need to conserve cash. Investors should be particularly concerned about the extensive legal and tax contingencies, especially the $451 million IRS proposed adjustment, which represents a material financial risk even if currently contested. The company's ability to navigate these legal challenges and successfully execute its restructuring plan will be critical for future performance.

At the time of this filing, XRAY was trading at $11.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $9.85 to $17.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed XRAY - Latest Insights

XRAY
May 05, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
9
XRAY
May 05, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
XRAY
May 05, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
XRAY
Apr 23, 2026, 4:32 PM EDT
Filing Type: DEF 14A
Importance Score:
8
XRAY
Mar 09, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
XRAY
Mar 03, 2026, 7:12 PM EST
Filing Type: 4
Importance Score:
7
XRAY
Feb 26, 2026, 5:58 PM EST
Source: Dow Jones Newswires
Importance Score:
8
XRAY
Feb 26, 2026, 5:06 PM EST
Source: dpa-AFX
Importance Score:
8
XRAY
Feb 26, 2026, 4:54 PM EST
Filing Type: 10-K
Importance Score:
8
XRAY
Feb 26, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8